Document is current
Any future updates will be listed below
-
Authors
Ise, Masataka
Iizuka, Hiromitsu
Kamoda, Yoshimasa
Hirao, Masako
Kida, Michiko
Usuki, Kensuke https://orcid.org/0000-0002-1216-4470
- License Information
-
More Information
Article History
Received: 11 May 2020
Revised: 29 July 2020
Accepted: 7 August 2020
First Online: 2 September 2020
Compliance with ethical standards
:
: Kensuke Usuki has received research funding from Astellas Pharma Inc., Alexion Pharmaceuticals, AbbVie GK, Gilead, SymBio Pharmaceuticals Ltd., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Novartis Pharma K.K., Bristol-Myers Squibb Company, Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Celgene Corporation, Takeda Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Mundipharma K.K., Astellas-Amgen-Biopharma KK, Apellis Pharmaceuticals Inc, Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., and Pfizer Japan Inc., and has served on speakers bureaus for Novartis Pharma K.K., Alexion Pharmaceuticals, Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., MSD K.K., Otsuka Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Ltd., Celgene Corporation, Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., PharmaEssentia Corp., Bristol-Myers Squibb Company, and Yakult Honsha Co. Ltd.
